Trimethoprim-sulfamethoxazole.
The antimicrobial combination of trimethoprim and sulfamethoxazole is active in vitro against a variety of gram-positive and gram-negative bacteria. Clinically, it is useful for treatment and prophylaxis of various infections of the genitourinary tract and certain infections of the respiratory and gastrointestinal tracts. Trimethoprim-sulfamethoxazole by itself or in combination with other antimicrobial agents is indicated for most Nocardia asteroides infections. It is the antimicrobial agent of choice for Pneumocystis carinii pneumonia. The drug is relatively nontoxic in patients who do not have acquired immunodeficiency syndrome (AIDS), and it is available in oral and intravenous forms. The native compounds and the metabolites of trimethoprim and sulfamethoxazole are excreted primarily in the urine. When the creatinine clearance decreases to less than 30 ml/min, the dosage of trimethoprim-sulfamethoxazole should be adjusted.
D001424:Bacterial Infections / Q000188:drug therapy; D004338:Drug Combinations / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D013420:Sulfamethoxazole / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D014295:Trimethoprim / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
D004338:Drug Combinations; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole